On June 9, 2026, RBC Capital raised its rating for Pfizer (NYSE: PFE) to Sector Perform from Underperform. Pfizer is a global pharmaceutical company that develops and manufactures a wide range of medicines and vaccines. At the time of the rating change, the stock price for Pfizer was $25.70.
This upgrade follows several positive developments. As highlighted by Zacks Investment Research, Pfizer is partnering with Amneal Pharmaceuticals for its glucagon-like peptide-1 (GLP-1) therapies. This deal provides Pfizer with manufacturing and supply support for its initiatives in the growing market for obesity and diabetes treatments.
Furthering its efforts in this area, Pfizer reported positive mid-stage trial data for its drug candidate, berobenatide. The company is aiming for this to be the first GLP-1 obesity therapy with a monthly dosing schedule. It now plans to start up to ten Phase 3 trials, which are late-stage studies to confirm a drug's effectiveness.
Separately, as announced by Business Wire, the U.S. Food and Drug Administration (FDA) approved an expanded use for Pfizer’s drug, HYMPAVZI. The approval now includes more patients with hemophilia A or B. The drug is used to prevent or reduce the frequency of bleeding episodes in both adults and children.
Shares of Pfizer are currently priced at $25.70, with a market capitalization of approximately $146.48 billion. Market capitalization is the total value of all a company's shares. The stock has traded between $25.47 and $25.88 during the day, with a 52-week range between $23.11 and $28.75.
